News Center

News Center

Shengshi Taikang's FGFR/VEGFR dual-target inhibitor approved for clinical trials to treat advanced solid tumors.

Shengshi Taikang's FGFR/VEGFR dual-target inhibitor approved for clinical trials to treat advanced solid tumors.

Recently, Shengshi Taikang announced that it has received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration (NMPA), granting permission to initiate a single-agent clinical trial of its investigational FGFR/VEGFR dual-target inhibitor CGT-6321 in patients with advanced solid tumors. This drug is poised to become China's potential first-in-class new therapeutic option.

Time：2021-10-22 09:25

Scientists, doctors, and investors in the diabetes field gathered at Hui Lecture Hall to discuss new drug development and clinical challenges.

Scientists, doctors, and investors in the diabetes field gathered at Hui Lecture Hall to discuss new drug development and clinical challenges.

Recently, scientists, clinicians, and financial investors in the field of sugar metabolism diseases gathered at the Hujiang Lecture Series event held at XJTLU’s School of Pharmacy, joining forces with professors from the same institution to actively share insights and engage in discussions on "Strategies and Roadmaps for Developing Next-Generation Drugs Targeting Sugar Metabolism and Related Diseases," covering key topics such as drug development trends, as well as the challenges inherent in research, innovation, and clinical application.

Time：2021-06-18 16:27

Shengshi Taikang Wins 2020 BioBAY Annual "Growth Award"

Shengshi Taikang Wins 2020 BioBAY Annual "Growth Award"

Though sifting through countless sands is laborious, only after blowing away the relentless dunes does the gold finally emerge. In the early days of entrepreneurship, a reed thriving amidst hemp plants naturally grows straight—no support needed. Yet when the time comes to assert oneself, one must rise alongside fierce competitors, battling fiercely before ultimately prevailing over them. Throughout history, no achievement has ever been attained without overcoming immense challenges—and lost precisely because of complacency. This is how growth truly happens!

Time：2021-01-27 16:43

Shengshi Taikang and Medicis Announce Strategic Collaboration on PROTAC Project

Shengshi Taikang and Medicis Announce Strategic Collaboration on PROTAC Project

Recently, Shengshi Taikang Biotechnology Co., Ltd. and MedicWest Biopharmaceuticals Co., Ltd. successfully established a strategic partnership on a PROTAC project. Under this collaboration, Shengshi Taikang will leverage MedicWest's proven expertise in PROTAC technology— a cutting-edge approach that diverges from traditional drug development strategies focused on inhibiting the activity or function of disease-causing proteins. Instead, PROTAC therapy harnesses the body’s natural protein degradation mechanisms to eliminate pathogenic target proteins, thereby modulating or treating diseases.

Time：2020-12-04 16:50

Shengshi Taikang's Yu Qiang: The innovative drug industry is a "Long March"—if you give up halfway, you lose.

Shengshi Taikang's Yu Qiang: The innovative drug industry is a "Long March"—if you give up halfway, you lose.

In 2020, the healthcare sector bucked the trend and surged ahead, sparking a "gold rush" in the capital markets. In terms of funding volume, healthcare companies raised at least nearly 200 billion yuan in the primary market during the first three quarters of this year—amounting to almost as much as Beijing’s total tax revenue for the entire first half of the year. As for growth speed, many companies saw their valuations skyrocket by multiples within just one year. “Recently, a reporter came to interview me, and I joked, ‘Right now, the sky above Suzhou smells like money,’” said Dr. Yu Qiang, founder of Shengshi Taike and a participant in the “Elite Leadership Development and Empowerment Program,” organized by the Enterprise Development Service Center of Suzhou Industrial Park and hosted by the Academy.

Time：2020-11-13 17:13

Shengshi Taikе partners with Yunxuan Pharmaceutical to broadly deploy CXCR4 antagonists.

Shengshi Taikе partners with Yunxuan Pharmaceutical to broadly deploy CXCR4 antagonists.

Recently, Shengshi Taikang, which focuses on both internal R&D and strategic external collaborations, announced that it has signed an exclusive cooperation and licensing agreement with Yunxuan Pharmaceutical, securing global exclusive rights for the development and commercialization of a preclinical-stage CXCR4 antagonist—a promising compound targeting chemokine receptor type 4.

Time：2020-04-16 17:16

Shengshi Taikang: The first domestically developed, original DPP-4 inhibitor, Sitagliptin, advances from "Phase 2 to Phase 3" without delay.

Shengshi Taikang: The first domestically developed, original DPP-4 inhibitor, Sitagliptin, advances from "Phase 2 to Phase 3" without delay.

Shengshi Taikang Biopharmaceutical Technology (Suzhou) Co., Ltd. is an innovative technology company dedicated to the research and development of antidiabetic drugs. The company’s newly developed phosphate senvogliflozin tablets are a novel DPP-4 inhibitor, boasting high potency and exceptional safety profiles. Notably, the drug was successfully selected twice—in 2012 and 2018—for China’s national key programs focused on the creation of major new medicines during the 12th and 13th Five-Year Plans, respectively. This year, data from a large-scale Phase I clinical trial have demonstrated that, compared to the positive-control drug sitagliptin, Shengshi Taikang’s phosphate senvogliflozin shows promising efficacy and remains safe and reliable for treating type 2 diabetes. Currently, the drug has received official approval from the National Medical Products Administration’s Center for Drug Evaluation, allowing it to skip Phase II clinical trials and proceed directly into Phase III testing.

Time：2019-11-14 17:17

Shengshi Taikang Secures Over 100 Million Yuan in A+ Round Funding Led by Hongtai

Shengshi Taikang Secures Over 100 Million Yuan in A+ Round Funding Led by Hongtai

(Suzhou, China – July 30, 2019) Shengshi Taikang Biopharmaceutical Technology (Suzhou) Co., Ltd. has secured a strategic A+ round of financing totaling over 100 million yuan, led by Hongtai Capital with participation from ABC International. This funding will primarily be used to advance the clinical trials of Shengglitine, a new diabetes treatment, as well as accelerate research progress on other innovative drug projects currently in development. Additionally, the company’s rare disease medications, which have already completed consistency evaluations, are set to launch into the market early next year.

Time：2019-07-30 17:23

< 1...5678 >
中企跨境-全域组件 制作前进入CSS配置样式

在线客服添加返回顶部

页面顺滑的滚动

屏蔽页面上图片的alt/title提示

右侧在线客服样式 1,2,3 2

图片alt标题设置： Fland Environmental

表单验证提示文本： The content cannot be empty!

循环体没有内容时： Content is being organized—please wait!

CSS / JS 文件放置地